FDA news

In April 2009, FDA completed its review of neuropsychiatric events, (mood and behavioral changes) possibly related to drugs that act through the leukotriene pathway (montelukast, zafirlukast, zileuton).  As part of its review, FDA reviewed post-marketing reports and also requested that manufacturers submit all available clinical trial data for these products.
2009年四月，关于作用于白细胞三烯的药物的神经作用的回顾性研究意见完成。
The post-market reports of patients on these medications included cases of neuropsychiatric events.  Some reports included clinical details consistent with a drug-induced effect.  In the clinical trial data submitted by manufacturers, neuropsychiatric events were not commonly observed.  However, the available data were limited because the trials were not designed to look for neuropsychiatric events.  Sleep disorders (primarily insomnia) were reported more frequently with all three products compared to placebo.